Second Leading Proxy Advisor Rejects Meir Jakobsohn's Attempt to Take Control of Knight Therapeutics' Board
- Glass Lewis becomes second leading proxy advisory firm to recommend that Knight shareholders reject Meir Jakobsohn’s scheme to take control of Knight; notes “lingering concerns” with respect to Mr. Jakobsohn’s “motivations and behavior”
- Glass Lewis joins ISS in recommending that “shareholders withhold votes from Mr. Jakobsohn”
- Shareholders are reminded to vote the BLUE Proxy in advance of the voting deadline of Friday, May 3, 2019 at 5:00 p.m. (EST)
- Questions? Need help? Contact Kingsdale Advisors at 1-888-518-1552 or at [email protected]